Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Advertisement
Set Alert for Articles By Brian Yang

Latest From Brian Yang

Pfizer Bets On Gene Therapy For Rare Diseases In China

After excluding China from its early development plans for domagrozumab, Pfizer’s rare disease R&D team is now gearing to commence a clinical study of the investigational compound on Duchenne muscular dystrophy patients soon.

Clinical Trials Rare Diseases

Asia Executives To Watch: Gilead, BMS, AZ In Japan, WuXi NextCode

Multinational drug makers continue shuffling their senior management in Asia as Gilead Sciences has a new president for Japan, and so does Bristol-Myers Squibb. WuXi NextCode hires a new chief digital officer.

Appointments Asia Pacific

AZ Sustains Strong China Growth Via Commercial Innovation

AstraZeneca’s strong showing in China in the third quarter was driven by a combination of expanded coverage, investment in patient access efforts and an innovative commercial model. New introductions Tagrisso and Farxiga are also expected to add to the momentum.

Commercial Launches

PTC Readies China Plan Amid US FDA Translarna Setback

PTC is engaging physicians and Duchenne muscular dystrophy patients in China to access a largely untapped market but regulatory and reimbursement-related uncertainties could pose challenges.

Clinical Trials Rare Diseases

BeiGene Unveils New Cancer Drug Plant With Eye On Affordability

A pure drug developer just a year ago, BeiGene has transformed itself into a full-fledged drug maker with its own R&D, manufacturing and commercial operations. But the Nasdaq-listed biotech is looking well beyond speed, including towards a thrust on quality, as it unveils a production site in Suzhou.

Commercial Strategy

Set, Ready, Walk: Gilead Unveils Sovaldi Strategy In China

Rapid regulatory changes in China are expected to trigger a flurry of new drug launch activities. As Q3 earnings season plays out, Gilead COO Kevin Young talks about doing ‘the right thing’ while rolling out products like the high-priced Sovaldi in China's private-pay market.

Asia Pacific Commercial
See All
Advertisement
UsernamePublicRestriction

Register